Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 3Thoracic 1Sarcoma 1NET 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Colorectal Neoplasms 14Lung Neoplasms 9Stomach Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Colonic Neoplasms 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Small Cell Lung Carcinoma 4Rectal Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Esophageal Neoplasms 4Melanoma 3Carcinoma, Renal Cell 3Carcinoma, Pancreatic Ductal 3Peritoneal Neoplasms 2Mesothelioma 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Vipoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thymoma 1Spinocerebellar Degenerations 1Somatostatinoma 1Sezary Syndrome 1Pseudomyxoma Peritonei 1

Interventions

Trastuzumab 2vatalanib 1tipifarnib 1pentetreotide 1Thalidomide 1Sunitinib 1Oxaliplatin 1Leucovorin 1Interleukin-12 Subunit p35 1Interleukin-12 1High-Energy Shock Waves 1Fluorouracil 1Fentanyl 1Everolimus 1Bevacizumab 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Somatostatinoma × Leucovorin × Thoracic × Clear all
NCT00227617 2023-05-22

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

University of California, San Francisco

Phase 2/3 Terminated
36 enrolled 14 charts
EndocrineNETThoracic

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Lung Neoplasms, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡